Skip to main content

Table 8 Responsiveness of measures over time to perceived benefit/harm; baseline to 12 months

From: An empirical evaluation of the SF-12, SF-6D, EQ-5D and Michigan Hand Outcome Questionnaire in patients with rheumatoid arthritis of the hand

  n T0 T12 Δ (95% CI) SRM (95% CI) ES (95% CI)
MHQ
 Benefit 276 51.15 57.83 6.68 (3.75 to 9.61) 0.26 (-1.74 to 2.27) 1.03 (-0.97 to 3.04)
 No benefit 110 50.86 49.15 -1.71 (-6.21 to 2.79) -0.07 (-3.18 to 3.05) 1.02 (-2.09 to 4.14
 Harm 6 46.33 46.34 0.01 (-20.65 to 20.67) 0.00 (-11.13 to 11.13) 1.22 (-9.91 to 12.35)
EQ-5D (utility)
 Benefit 276 0.59 0.61 0.06 (0.02 to 0.10) 0.17 (0.14 to 0.19) 0.24 (0.20to 0.26)
 No benefit 110 0.59 0.57 -0.03 (-0.09 to 0.03) -0.09 (-0.14 to -0.05) -0.13 (-0.17 to -0.08)
 Harm 6 0.53 0.54 -0.05 (-0.03 to 0.23) -0.15 (-0.25 to -0.03) -0.22 (-0.34 to -0.09)
EQ-5D (VAS)
 Benefit 276 69.57 67.92 -1.65 (-3.67 to 0.37) -0.06 (-2.08 to 1.96) -0.08 (-2.10 to 1.94)
 No benefit 110 64.89 61.3 -3.59 (- 7.08 to -0.09) -0.13 (-3.63 to 3.35) -0.19 (-3.68 to 3.30)
 Harm 6 60.16 57 -3.16 (-19.83 to 13.56) -0.11 (-16.83 to 16.61) -0.15 (-16.87 to 18.42)
SF-12 (PCS)
 Benefit 276 34.44 32.93 -1.51 (-2.77 to -0.24) -0.08 (-1.35 to 1.18) -0.12 (-1.38 to 1.15)
 No benefit 110 31.79 31 -0.79 (-2.86 to 1.28) -0.15 (-2.13 to 2.02) -0.08 (-2.15 to 1.99)
 Harm 6 24.84 36.08 11.24 (-0.27 to 22.75) 0.67 (-10.84 to 12.19) 0.99 (-10.52 to 12.51)
SF-12 (MCS)
 Benefit 276 48.26 47.31 -0.95 (-2.44 to 0.54) -0.05 (-1.54 to 1.45) -0.06 (-1.56 to 1.42)
 No benefit 110 48.04 49.44 1.4 (-1.06 to 3.86) 0.08 (-2.38 to 2.54) 0.12 (-2.34 to 2.57)
 Harm 6 32.7 37.74 5.04 (-11.59 to 21.67) 0.21 (-16.42 to 16.84) 0.31 (-16.32 to 16.95)
SF-6D
 Benefit 276 0.64 0.63 -0.01 (-0.03 to 0.01) -0.04 (-0.06 to -0.02) -0.06 (-0.07 to -0.04)
 No benefit 110 0.63 0.63 0 (-0.02 to 0.02) 0 (-0.02 to 0.02) 0 (-0.02 to 0.02)
 Harm 6 0.58 0.58 0 (-0.06 to 0.06) 0 (-0.06 to 0.06) 0 (-0.06 to 0.06)